Form 4: LIXT Director Michael Holloway Granted Stock Options

LIXTE Biotechnology Holdings, Inc. Director Michael Holloway received 25,000 stock options with an exercise price of $3.59 per share, vesting over time.

Summary

• Michael Andrew Holloway, a Director of LIXTE Biotechnology Holdings, Inc. (LIXT), was granted 25,000 stock options.
• The options have an exercise price of $3.59 per share.
• The grant was effective August 15, 2025, and was made in connection with Michael Holloway's appointment to the Company's Board of Directors.
• Vesting schedule dictates 50% of the options vest on the effective date (August 15, 2025).
• The remaining 50% will vest at 12.5% on December 31, 2025, and on the last day of each subsequent calendar quarter until fully vested, subject to continuous service.
• The options expire on August 15, 2030.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a positive step towards aligning management interests with shareholder value, reflecting standard corporate governance practices.

Positives

• The grant of stock options aligns the financial interests of Director Michael Holloway with those of the shareholders, incentivizing long-term value creation.
• This is a standard practice for compensating directors, reflecting a commitment to attracting and retaining qualified board members.

Risks

• The vesting of the remaining 50% of the options is subject to Michael Holloway's continuous service, meaning unvested options could be forfeited if service ceases.

Future Outlook

The vesting schedule for the stock options extends into future calendar quarters, indicating an expectation of continued service from Director Michael Holloway and a long-term incentive structure.

Industry Context

Granting stock options to directors is a common compensation practice across various industries, including biotechnology, to align leadership incentives with company performance and shareholder returns.

Comparison to Industry Standards

• The practice of compensating directors with equity, such as stock options, is a widely accepted standard in corporate governance across the biotechnology sector and broader public markets.
• Specific comparisons of the number of options or exercise price to industry benchmarks would require detailed analysis of compensation packages for directors at comparable biotech companies, considering factors like company size, stage of development, and market capitalization.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align their interests with shareholder value, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• Continued service by Michael Holloway for the vesting of the remaining stock options.

Key Dates

Keywords

LIXTE Biotechnology Holdings, LIXT, Stock Options, Director Compensation, Insider Transaction, Form 4, Equity Grant